Clinical Implications of Vasoactive Intestinal Peptide and 5-Hydroxytryptamine in Diabetic Neurogenic Bladder and Their Relationship with Post-Void Residual Urine Volume

  • Long Shi Department of Urinary Surgery, The Affiliated Suqian Hospital of Xuzhou Medical University, Nanjing Drum Tower Hospital Group Suqian Hospital, Suqian, Jiangsu, 223800, China.
  • Shaoqi Zhang Department of Urinary Surgery, The Affiliated Suqian Hospital of Xuzhou Medical University, Nanjing Drum Tower Hospital Group Suqian Hospital, Suqian, Jiangsu, 223800, China.
  • Longjun Cai Department of Urinary Surgery, The Affiliated Suqian Hospital of Xuzhou Medical University, Nanjing Drum Tower Hospital Group Suqian Hospital, Suqian, Jiangsu, 223800, China.
  • Jianjun Zhang Department of Urinary Surgery, The Affiliated Suqian Hospital of Xuzhou Medical University, Nanjing Drum Tower Hospital Group Suqian Hospital, Suqian, Jiangsu, 223800, China.
  • Gao Liu Department of Urinary Surgery, The Affiliated Suqian Hospital of Xuzhou Medical University, Nanjing Drum Tower Hospital Group Suqian Hospital, Suqian, Jiangsu, 223800, China.
  • Xiangyu Wang Department of Urinary Surgery, The Affiliated Suqian Hospital of Xuzhou Medical University, Nanjing Drum Tower Hospital Group Suqian Hospital, Suqian, Jiangsu, 223800, China.
  • Furong Ji Department of Urinary Surgery, The Affiliated Suqian Hospital of Xuzhou Medical University, Nanjing Drum Tower Hospital Group Suqian Hospital, Suqian, Jiangsu, 223800, China.
  • Yongming Sun Department of Urinary Surgery, The Affiliated Suqian Hospital of Xuzhou Medical University, Nanjing Drum Tower Hospital Group Suqian Hospital, Suqian, Jiangsu, 223800, China.
  • Zhongqing Wei Department of Urinary Surgery, The Second Affiliated Hospital of Nanjing Medical University
DOI: https://doi.org/10.5937/jomb0-62295
Keywords: Vasoactive Intestinal Peptide, 5-Hydroxytryptamine, Diabetic Neurogenic Bladder, Post-Void Residual Urine Volume, Diagnostic and Prognostic Biomarkers

Abstract


Objective: To elucidate the clinical significance of vasoactive intestinal peptide (VIP) and 5-hydroxytryptamine (5-HT) in diabetic neurogenic bladder (DNB). A key objective is to determine the diagnostic, stratifying, and prognostic value of their simultaneous detection, and to reveal the dynamic associations of these biomarkers with post-void residual urine volume (PVR).

Methods: The study population consisted of 30 DNB patients and 30 healthy individuals from the same timeframe (June 2024-April 2025). Laboratory assessments quantified serum VIP concentration by enzyme-linked immunosorbent assay (ELISA) and 5-HT concentration by liquid chromatography-mass spectrometry (LC-MS). PVR quantification relied on urodynamic examination and abdominal ultrasound. Over a 3-month follow-up, serial measurements of VIP and 5-HT were obtained. Statistical analyses, including Pearson correlation, receiver operating characteristic (ROC) curve analysis, and logistic regression modeling, were employed to assess the relationships of these biomarkers with PVR, bladder function classification, and patient prognosis.

Results: Significant reductions in VIP and 5-HT were observed in DNB patients relative to controls (P<0.05). The combined use of VIP and 5-HT achieved an AUC value of 0.878, with 83.33% sensitivity and 86.67% specificity, indicating better diagnostic efficacy than single-marker detection (P<0.05). VIP and 5-HT levels were inversely related to PVR (P<0.05). In DNB patients, both biomarkers increased gradually at one and three months post-treatment (P<0.05), paralleling urodynamic improvements. Patients with lower VIP and 5-HT levels three months after treatment had a greater propensity for upper urinary tract impairment, urinary tract infections, and disease advancement.

Conclusion: The combined detection of VIP and 5-HT enables effective evaluation of DNB severity, forecasts disease progression, and offers a foundation for timely intervention through dynamic monitoring.

Published
2025/11/23
Issue
Ahead of print
Section
Original paper

Copyright (c) 2025 Long Shi, Shaoqi Zhang, Longjun Cai, Jianjun Zhang, Gao Liu, Xiangyu Wang, Furong Ji, Yongming Sun, Zhongqing Wei

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.